Terbequinil

Drug Profile

Terbequinil

Alternative Names: SR 25776

Latest Information Update: 07 Jan 1997

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Class Antidementias; Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action GABA A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cognition disorders; Major depressive disorder

Most Recent Events

  • 07 Jan 1997 Discontinued-I for Depression in France (Unknown route)
  • 12 Aug 1996 Discontinued-I for Cognition disorders in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top